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The majority of people infected with chronic hepatitis C virus (HCV) in the European 
Union (EU) remain undiagnosed and untreated. During recent years, immigration to 
EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 
million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) 
countries, as many as 580,000 are migrants. Additionally, HCV is highly prevalent and 
under addressed in Eastern Europe. In 2013, the introduction of highly effective 
treatments for HCV with direct acting antivirals created an unprecedented 
opportunity to cure almost all patients, reduce HCV transmission and eliminate the 
disease. However, in many settings, HCV elimination poses a serious challenge for 
countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy 
Association held the 2nd EU HCV Policy summit. It was emphasized that key 
stakeholders should work collaboratively since only a few countries in the EU are on 
track to achieve HCV elimination by 2030. In particular, more effort is needed for 
universal screening. The micro-elimination approach in specific populations is less 
complex and less costly than country-wide elimination programmes and is an 
important first step in many settings. Preliminary data suggest that implementation 
of the World Health Organization (WHO) Global Health Sector Strategy on Viral 
Hepatitis can be cost saving. However, innovative financing mechanisms are needed 
to raise funds upfront for scaling-up screening, treatment and harm reduction 
interventions that can lead to HCV elimination by 2030, the stated goal of the WHO. 
Key words: Prevention, burden, care, elimination, health policy, high-risk 
populations, surveillance, treatment, viral hepatitis.
































































On 6 June 2018, the Hepatitis B and C Public Policy Association (HepBCPPA)* held 
the 2nd European Union (EU) hepatitis C virus (HCV) Policy summit entitled “Securing 
sustainable funding for hepatitis elimination plans” in Brussels, Belgium. This high-
level conference represented the next major step towards the elimination of 
hepatitis C in Europe. Τhe main stakeholders in the field of hepatitis C were gathered 
together: clinicians, patient associations, representatives of key institutions and 
regional bodies from across Europe to present the case for a European elimination 
strategy for hepatitis C in the presence of EU and national policymakers1,2.
During the Summit, the case was made for the need to ensure that the cost of HCV 
elimination (i.e. surveillance, monitoring, awareness, screening prevention and 
treatment programs) is cost-saving 1,2. The European institutions and stakeholders 
represented were the European Parliament Friends of the Liver MEP group, the 
European Liver Patients’ Association (ELPA), the European Association for the Study 
of the Liver (EASL), the Correlation European Harm Reduction Network (C-EHRN) & 
European Civil Society Forum, the Centre for Disease Analysis Foundation, and the 
World Health Organization (WHO). In addition, several members from national 
parliaments attended the summit. In total, 90 delegates attended the event with 29 
different nationalities present. 
*Footnote: HepBCPPA is a non-profit organization that brings together a wide range of 
thought-leaders and stakeholders to reflect on recent advances and challenges in 
understanding, measuring, preventing, diagnosing and treating hepatitis B and C and to 
develop policy responses that can effectively and measurably address these challenges. Over 
the past 9 years, HepBCPPA has organised three high-level meetings and two EU HCV Policy 
summits in cooperation with the EU Presidency of Belgium, the EU Presidency of Cyprus, the 
EU Presidency of Greece and the European Commission and has initiated and agreed with its 
partner associations on five Calls to Action addressed to the European Commission and the 
EU Member States. 































































Overview and Background of HCV epidemiology
Global burden of HCV: need for action to overcome barriers 
Hepatitis C remains a global health problem and it continues to have a large human, 
social and economic impact 3. According to the most recent WHO global hepatitis 
report, 71 million people are chronically infected by hepatitis C, and of these, 80% 
are undiagnosed, mostly because they are asymptomatic and 93% remain untreated 
4. Even in countries with high levels of hepatitis C awareness, less than 40% of the 
infected patients have been diagnosed and an even lower proportion received 
antiviral therapy. Globally, more than 1,095 people die from HCV every day and 
400,000 people die every year from HCV-related liver diseases even though HCV is 
curable with the availability of direct acting antivirals (DAAs)5,6. 
Although HCV continues to spread as a largely “silent pandemic,” its elimination is 
made possible through the availability of new, safe and effective treatments for HCV 
with direct acting antivirals (DAAs) and the implementation of prevention practices. 
However, in the majority of countries, HCV elimination represents a serious 
challenge for countries’ health budgets as they are faced, for the first time in history, 
with a fast-acting curative high-cost treatment for a widespread, chronic viral 
disease that offers little risk of resistance or relapse. In addition to treatment costs, 
the cost of scaling up testing to find the non-identified infected individuals and 
implementing effective models of care for diverse populations represents additional 
challenges. On the other hand, the European economic crisis has impacted public 
health spending more than on any other public life sector with shrinking budgets. On 
28 May 2016, WHO published the Global Health Sector Strategy on viral hepatitis, 
which was endorsed by all member states at the World Health Assembly and  called 
for the elimination of viral hepatitis as a public health threat by 2030 and set the 
targets at two time points (2020 and 2030) as shown in Figure 1 7.  
However, several barriers and gaps in the cascade of care should be addressed and 
overcome and solutions need to be found and subsequently funded. All stakeholders 
and decision makers, such as policy-makers, healthcare providers, insurance 
providers and the industry, should work together and collaborate in order to achieve 
the necessary scale-up for hepatitis C elimination. This aim is very ambitious and 
there is an urgent need to improve the services needed to reach and better 
understand the specific characteristics (culture, language etc) of each subgroup, e.g. 
migrants, men who have sex with men (MSM) and people who inject drugs (PWID). 































































European burden of HCV
It is estimated that 3.0 million people are live with infected with chronic hepatitis C 
virus in the EU, and of these, 68% are undiagnosed and less than 6% have been 
treated. In addition, despite the availability of DAAs, 16,000 patients were diagnosed 
with hepatocellular carcinoma (HCC) and 22,500 deaths related to chronic hepatitis C 
were recorded in 2017, i.e. every 25 minutes, an HCV-infected person died of liver 
complications in the EU in 20178, 9. 
Hepatitis C represents a major burden in the EU. The cost of inaction is great – 
136,000 additional deaths, 90,000 additional HCC cases, and 71,000 decompensated 
cirrhosis cases are estimated between 2017 and 2030. Even EU countries with a high 
treatment rate will not be able to sustain the treatment without universal screening 
and political-will is the main predictor of whether a country will achieve the 2030 
elimination targets. 
Although the epidemiology of hepatitis C in Europe seems well characterizedThe 
understanding of HCV epidemiology in Europe is advancing, during recent years, 
although migration has become a challenge. In the 31 EU/ European Economic Area 
(EEA) countries, it has been estimated that, out of the 4.2 million adults affected by 
HCV infection, as many as 580,000 are migrants, i.e. 14% of the total HCV burden 10. 
Thus, migrants contribute significantly to the EU/EEA HCV burden, since 79% of them 
originate from endemic countries 10.   Another challenge is represented by the 
situation in Eastern Europe, where a hepatitis C epidemic is exploding, driven by 
injecting drug use. Here, the outlook is worrysome, due to a general lack of 
awareness, the absence of surveillance systems, the limited national strategies, little 
or no funding for hepatitis programs, and often obsolete management programmes 
11. 
Elimination of HCV in Europe: need for collaboration
Key organizations and associations should collaborate for hepatitis C elimination in 
Europe by 2030. In this context, the EASL has organized several projects, such as 
HEPAHEALTH, aiming to better describe the incidence, prevalence and mortality of 
viral hepatitis across Europe 12.  On the other hand, Friends of the Liver Member of 
the European Parliament (MEP) Group work to put hepatitis C as an urgent health 
priority at European and national levels promoting policy action and educational 
programs to increase screening, diagnosis and eliminate stigmatization 13. 
Correlation – European Harm Reduction Network trains community members and 
harm reduction workers and informs policy maker to increase access to testing and 
care 14. Finally, ELPA has taken action and launched the Hep-CORE Study – which 
monitors the implementation of hepatitis B and C policy recommendations in Europe 































































in an attempt to shed light on national policies on viral hepatitis 15. In addition, ELPA, 
in collaboration with the INTEGRATE European Joint Action, launched a pilot 
campaign “Spring European Hepatitis-HIV Testing Week 2018” aiming to promote 
wide-scale testing for hepatitis and HIV and to identify barriers that participants 
experience when implementing integrated testing in different settings across 
Europe16,17. 
 Burden of disease and pathways of elimination
What is the state of play of HCV elimination in the EU?
Currently, few countries in Europe (France, Georgia, Iceland, Italy, Netherlands, 
Spain, Switzerland and United Kingdom) are on track for HCV elimination by 2030 6, 8. 
Fortunately, the actual number of treated patients with hepatitis C has increased 
over the last few years since DAAs have become available. At this rate, the EU only 
needs to diagnose 160,000 (from today’s 90,000) and treat 180,000 (from 160,000 
today) annually to reach the 2030 WHO elimination target (Figure 2)6, 8. However, 
the number of people that need to be screened (each year) will have to significantly 
increase in order to find the remaining undiagnosed individuals: from 5 million 
people currently screened to 40 million people in 2028 (Figure 2). In addition, in 
many European countries the initial increase in the treated patients after the 
implementation of DAAs was followed – or are expected to be followed - by a 
decline of treated patients (Figure 3)6, 8. In order to achieve the 2030 elimination 
targets seven requirements are needed: 1) financing of the national elimination 
program, 2) implementation of harm reduction programs, 3) expand capacity 
beyond specialists, 4) remove treatment restrictions, 5) implement monitoring & 
evaluation, 6) implement awareness and national screening programs, 7) implement 
national linkage to care program. 
Eliminating hepatitis C: the impact of the micro-elimination approach 18
The WHO targets for HCV elimination are challenging, costly and complex. However, 
the continuum of viral hepatitis services and the retention cascade need 
simplification similar to those of HIV infection. In addition, it should be recognized 
that elimination of hepatitis C is still a daunting task for health systems. However, an 
idea is to break down this cost by subgroup or population, by year, or region, for 
example. In fact, formidable obstacles to reaching HCV elimination can best be 
overcome through a micro-elimination approach, which entails pursuing elimination 
goals in specific populations. Micro-elimination is less daunting, less complex, and 
less costly than full-scale, country-level initiatives to eliminate HCV, and it can build 
momentum by producing small victories that inspire more ambitious efforts. The 































































micro-elimination approach encourages stakeholders who are most knowledgeable 
about specific populations to engage with each other and also promotes the uptake 
of new models of care 18. 
A successful micro-elimination approach should meet the following four criteria, 
although these criteria may need to be adapted to different epidemiologic situations 
and geographic settings: a) there should be a plan in order to tailor health resources 
and services with the aim of overcoming known barriers and achieving high levels of 
HCV diagnosis and treatment rates in one or more clearly defined populations of 
interest within a specified timeframe, which can be faster than in the general 
population, b) the plan sets forth achievable annual targets, basing these on 
mathematical modeling when relevant to determine the levels of diagnosis and 
treatment required to progress to the plan’s ultimate elimination targets, c) the plan 
is developed and implemented through a multi-stakeholder process, with essential 
participants including g vernment officials, health service providers, civil society and 
community representatives and d) progress and outcomes need to be monitored 
and publicly reported using indicators selected at the outset of the process 19.
HCV micro-elimination can be feasible in certain populations in the short-to-
medium- term such as patients with decompensated cirrhosis, veterans/military 
personnel, patients with haemophilia, transplant patients, HIV/HCV co-infected 
patients and sub-groups of PWID and prisoners. However, candidate populations can 
be expected to vary greatly in different countries and subnational areas 20. Some of 
these populations are more challenging than others, but HCV elimination can be 
facilitated by employing a people-centered health system approach with all key 
stakeholders engaged, including policy-makers, academics, healthcare providers, civil 
society and industry.
Progress report towards elimination by 2030 globally and in Europe 21
The WHO Global Health Sector Strategy on viral hepatitis, 2016–2021 includes three 
organizing frameworks: universal health coverage (UHC), continuum of health 
services, and the public health approach 21. To reinforce the commitment of the 
global goal, members of the EU have endorsed the first European action plan in 
September 2016 21. Based on this plan, several regional essential targets should be 
reached by 2020 regarding prevention, and particularly, testing and treatment. It is 
encouraging that the number of European countries with national plans increased 
from 13 in 2013 to 22 in 2017 21. However, several challenges remain especially in 
low and middle-income countries, since there is a lack of global donors and 
commitment in many countries, data is patchy and monitoring systems are nascent, 
most people living with hepatitis are still undiagnosed, treatment access is limited by 
regulatory barriers and high prices, particularly for newer antiviral drugs.  































































Cost of HCV elimination: Direct medical cost, patients reported outcomes and 
productivity loss
Several studies have shown that patient-reported outcomes (PROs) and work 
productivity (WP), both important components of comprehensive outcomes 
assessment, are impaired in HCV infected patients 22. PROs are important surrogate 
markers of patient experience, and their impairment, especially in the domains of 
physical functioning and mental health, is the result of the virus replicating itself. 
Regarding WP, HCV appears to affect absenteeism from work leading to a substantial 
economic burden to employers 23. As a result, although in 2011 the total direct cost 
of HCV-related liver disease had been estimated at USD 6.5 billion in the USA 
(projected to peak at 9.1 billion in 2014), the indirect economic burden of WP loss in 
the USA has been estimated to be approximately USD 7.1 billion per year and EUR 
2.6 billion per year in 5 major European countries (France, Germany, Italy, Spain and 
United Kingdom) 22,24. Importantly, PROs and WP are improved during treatment 
with antiviral therapy with DAAs, and this improvement is sustainable and durable 
after successful antiviral therapy with DAAs leading to clinical, PRO and economic 
gains 25.
Cost of screening
Many patients have advance clinical stage of liver disease with or without severe 
complications at the time of diagnosis. For example, in France, 12% of patients had 
cirrhosis and/or hepatocellular carcinoma at the time of referral at hepatology 
centres 26.
HCV screening guidelines still target only people at high risk of infection, but this 
approach requires reconsideration in the light of treatment with DAAs. In addition, 
the later can be used as a means of prevention, particularly in high-risk populations, 
such as MSM and PWIDs. For example, DAA treatment can reverse the HCV epidemic 
over the next ten years among MSM in the United Kingdom, particularly for those 
with recent HCV diagnosis 27. Similarly, in France and Scotland, treatment with DAAs 
may have a great impact reducing the prevalence of HCV infection and liver-related 
morbidity in PWIDs 28,29. 
Although there is great heterogeneity across European countries, the need to 
improve HCV screening is widespread (e.g. in France 100,000 people have chronic 
hepatitis C and half of them were undiagnosed by 2018). Interestingly, according to 
five different mathematical models regarding effectiveness, cost and cost-
effectiveness in France, showing that universal (100%) screening coverage plus 
treatment initiation regardless of fibrosis stage (i.e. from fibrosis F0) can reduce the 































































prevalence of HCV by 94% after one year, compared to 40% reduction with 50% 
screening coverage plus treatment initiation regardless of fibrosis stage. The latter 
model can reduce the incidence of HCV cirrhosis by 30% (or by 73% with 100% 
screening coverage) after ten years. In addition, the model of universal (100%) 
screening coverage plus treatment initiation regardless of fibrosis stage seems to be 
cost-effective (31,100 €/QALY), in contrast with when treatment is given only to 
those with fibrosis ≥F2 30, 31. Based on these findings, a National Health Strategy was 
announced in France in 2018 recommending actions in order to strengthen: a) access 
to hepatitis C treatment for all; b) proximity to screening by rapid diagnostic 
orientation testing in a combined approach to HIV, HBV and HCV) prevention 
through innovative "go-to-go" actions to reach priority and bring audiences into the 
health system.
Is hepatitis C elimination cost-saving?
While HCV treatment may be cost-saving, but still hepatitis C elimination program 
may not be cost-saving if the cost of diagnosing HCV cases is high. Globally, 
treatment with DAAs can reduce the burden of HCV-associated disease by 50%-70% 
between 2015 and 2050; liver-related deaths (from 767,000 without treatment to 
317,000); hepatocellular carcinoma (from 407,000 without treatment to 154,000); 
and liver transplants (from 63,000 without treatment to 31,000) 32, 33.
Data from the United Kingdom have shown that in an elimination scenario, 
compared to the current status quo, an initial investment is needed, but then a 
significant reduction in the cost is expected over the next few years (Figure 4). Thus, 
it is estimated that the total cost (natural history, diagnosis and treatment) over the 
next twenty years is about 11.7 billion dollars with current status quo, compared to 
10 billion dollars with elimination scenario (i.e. saving 1.7 billion dollars) (Figure 
5)[31]. Resources spent on HCV elimination provide good value for money and will 
result in cost-savings. Thus, HCV elimination is feasible and will save lives. 
Interestingly, the WHO has developed an online cost-effectiveness tool, Hep C 
Calculator (http://www.hepccalculator.org/), for estimation of cost-effectiveness of 
hepatitis C treatment in 28 countries. The tool also estimates how long will it take for 
treatment to become cost-effective/saving based on country-specific data.
Innovative financing 
Elimination of HCV requires strong collaboration between stakeholders. The plan for 
HCV elimination should be achievable, sustainable and follow the WHO time frame 
34. There is general consensus that one of the crucial factors to achieving this goal is 
adequate funding for the continuum of care to support the HCV elimination 































































initiative. Financing remains a major barrier and making the treatment affordable is 
still a major challenge for many European countries. 
Innovative financing for HCV elimination 35
New sources of funding will be required for countries to launch, accelerate and 
sustain public health responses to eliminate viral hepatitis. These resources will need 
to be substantial to meet elimination targets. It is true that for HCV elimination, 
investment is needed over a long period of time (e.g., providing antiviral treatment 
until 2030), but since HCV is a slow progressive disease, the return on investment 
will accrue after a long time. Through bond finance, not only can governments 
release money for public spending, but the maturity period can be adjusted to the 
timeframe in which the investment produces the desired social/economic benefit. 
One option could be commercial bonds, which are widely used in the public sector 
for funding infrastructure projects, while vaccine bonds were developed by the 
International Finance Facility for Immunization (IFFIm)36. Another option could be 
social impact bonds, i.e. a contract with the public sector in which a commitment is 
made to pay for improved social outcomes that result in public sector savings (e.g., 
social bond for rehabilitation of incarcerated people and to reduce recidivism) 35. 
Based on these experiences, it was suggested at the Summit that the establishment 
of an “HCV bond” could be an effective and realistic option to finance hepatitis C 
elimination providing a good return on investment (the more we treat, the more 
lives saved and more economic savings) (Figure 6). 
As George Papandreou, President of the Socialist International, and former Prime 
Minister of Greece and keynote speaker at the 2nd EU HCV Policy summit 
mentioned, some European countries have already important experience in creating 
social bonds and similar financing tools. Other countries may prefer to explore 
opportunities through cooperation with the European Financial Institutions such as 
the European Investment Bank. Thus, the EU Commission could prepare the 
legislative actions, to convincingly motivate the European Investment Bank and 
other European financial institutions to take this ambitious yet totally realistic 
project on board 37.
Financing of viral hepatitis elimination in low and middle-Income Countries 38
Although hepatitis elimination has a positive return on investment– the main 
problem is the need for upfront investment. An alternative approach could be based 
on patients who are willing to pay for healthcare expenses (for example in many of 
the lower middle-income countries, a high proportion of patients of all treatments 
are currently in the private market) providing that the costs are kept below the 































































catastrophic healthcare expenditure level, while some portion of the population will 
not be able to pay for their healthcare. This model can be supported by suppliers 
who are willing to provide price concessions if large volumes are guaranteed, as well 
as banks and donors who are willing to provide catalytic financing if they have 
assurances that can get their investment back at the end of the program 38. 
The new model would foresee the use of loans instead of donations to support the 
hepatitis elimination programs. Thus, although the old model based on donations 
(donations from the few pay for the needs of the many, including for those who 
could afford some payment), in the proposed new model, patients fund their 
treatment (small loan from investor, plus funds from many patients, pay for 
diagnostics and treatment for all, plus repayment to investor). 
Nevertheless, since the cost of treatment is an important issue, a holistic approach is 
needed, including: a) pooled procurement of licensed generic DAAs and quality-
assured diagnostic tests at volume discount; b) negotiations for waiving of import 
duties, taxes and pharmacy markups, to keep prices affordable; and c) enforcement 
of negotiations with the pharmaceutical industry and producers of diagnostic tools 
using digital voucher technology, eliminating cash transactions and opportunistic 
pricing.
Challenges and opportunities
The economic crisis has led to cuts in funding for harm reduction in many countries. 
Thus, there is a need to move towards a single-visit hepatitis C diagnosis, instead of 
the five-visits of the interferon era, in order to decrease the time of diagnosis (from 
4-6 weeks or more to no delay) and the rates of lost follow up. The new treatment 
options give this opportunity, since hospital attendance requirements are evidenced 
barriers particularly for marginalized populations. In this direction, more efforts are 
needed to increase screening in risk groups and build capacity for treatment as well 
as to raise awareness of viral hepatitis amongst the general population and general 
practitioners, and to improve diagnosis of HCV in primary care settings providing 
sustainable, affordable, universal access to the tools for elimination. Political 
leadership may play an important role in delivering the message of hepatitis C 
elimination at the political level by keeping hepatitis C high on the political and 
media agendas 39. It is important to build on support of the European Parliament and 
to influence the agenda of the next European Commission and the governments of 
EU Council Presidencies during the transition in 2019-2020 aimed to improve 
diagnosis and access to treatment amongst defined key groups, such as PWID 16. 
The Correlation European Harm Reduction Network, focused on hepatitis C since 
2014, provides models to improve access and quality of health and social services for 
marginalised groups and more than 220 partners in all European countries 































































participate 39. Finally, an organized network of Parliamentarians is needed, in order 
to increase their involvement in international - multilateral workgroups and decision 
processes aiming to reboot the political awareness and action towards elimination of 
hepatitis C 40.
Conclusions 
The Call to Action of the 2nd EU HCV Policy Summit recommends that countries have 
a comprehensive, costed hepatitis C elimination strategy in place to determine their 
country-level disease and economic burden of HCV by measuring direct and indirect 
socio-economic costs to improve the response towards HCV elimination and to 
develop country and population-specific models, to estimate lifetime costs, quality-
adjusted life expectancy, and incremental cost-effectiveness ratios of different 
screening and treatment strategies in comparison with no action. These are 
necessary to hepatitis elimination programs as hepatitis investment cases. 
Innovative financing tools include social impact bonds, with the aim to raise upfront 
funds for launching new social services and financing prevention services, including 
harm reduction, contributing to HCV elimination in a sustainable way. 
The European Union should recognize the need to engage in HCV elimination by 
establishing a clear political roadmap and call for European financial institutions to 
raise public and/or private funding and use elimination programs as development 
and health systems strengthening tools, encourage and engage all the stakeholders, 
including the European Union, to collaborate in the development of innovative 
financing tools.
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Figure 1. The WHO targets for HCV elimination at two time points (2020 and 2030).
Figure 2. The number of people in the European Union (EU) that need to be 
screened, diagnosed and treated annually to reach the 2030 WHO elimination 
targets. The EU needs to diagnose 160,000 & treat 180,000 annually to reach the 
2030 WHO elimination targets. The number of people that need to be screened 
(each year) will have to increase to find the remaining undiagnosed individuals.
Figure 3. In many European countries the initial increase in the treated patients after 
the implementation of Direct acting antivirals (DAAs) was followed by a decline of 
treated patients indicating that it is difficult to continue to treat the same number of 
patients.
Figure 4. Cost of HCV Elimination versus Status Quo in the United Kingdom over the 
next twenty years. In the elimination scenario an initial investment is needed, but 
then a significant reduction in the cost is expected.
Figure 5. Total cost of hepatitis C Elimination versus Status Quo in the United 
Kingdom. With elimination scenario, saving 1.7 billion dollars is estimated.
Figure 6. An “HCV bond” could be an effective to finance hepatitis C elimination since 
after few years the marginal cost is negative resulting in cost saving.
































































Call to Action to “Secure sustainable funding for viral hepatitis C elimination plans”
The hepatitis C virus (HCV) is a global public health threat with significant morbidity 
and mortality. Due to its asymptomatic nature, it is also a silent epidemic with an 
estimated 71 million infected globally, but only 20% diagnosed.
In 2013, the introduction of new, safe and effective treatments for HCV created an 
opportunity to eliminate the disease. However, in some settings, this development 
represents a serious challenge for countries’ health spending as they are faced, for 
the first time in history, with a fast-acting curative treatment for a widespread 
chronic viral disease which offers little risk of resistance or relapse. In addition to 
treatment costs, the cost of scaling up testing to find the non-identified infected 
individuals and implementing effective models of care for diverse populations, 
represent an additional challenge.
Greater efforts are needed to ensure that all elements of cost of HCV elimination, 
which include surveillance, monitoring, awareness, screening, prevention and 
treatment programs, are affordable. Preliminary data suggest that the WHO HCV 
elimination strategy may be cost-saving for many countries. That is the savings 
related to preventing and treating HCV may exceed the cost of HCV elimination, 
providing good value for money given the high initial spending. Strategic Direction 4 
of the WHO Global Health Sector Strategy on Viral Hepatitis 2016-2021 “Financing 
for sustainability” sets out financing recomm ndations for a sustainable hepatitis 
response, outlining actions to raise revenue to pay for viral hepatitis interventions 
and services, set-up financial risk protection, and improve efficiency in the use of 
health system resources.
On 17 February 2016, the launch of the HCV Elimination Manifesto “Our vision for a 
Hepatitis C-free Europe”, provided a starting point for action to make HCV and its 
elimination in Europe an explicit public health priority. With patients, civil society 
groups and other relevant stakeholders directly involved in developing and 
implementing HCV elimination strategies, now is the time to take the next step 
further and make the HCV elimination affordable.
We, the signatories of the Call to Action “Secure sustainable funding for hepatitis C 
elimination plans” are committed to HCV elimination in Europe.
In line with the 2015 United Nations’ General Assembly Resolution “Transforming 
our world: the 2030 Agenda for Sustainable Development”, in line with the 
Sustainable Goal 3 Good Health and Well-Being and its Target 3.3 to Fight 
Communicable Diseases, in line with the 2014 World Health Assembly’s Resolution 
67.6 on hepatitis, in line with the 2016 HCV Elimination Manifesto, in line with the 
WHO Global Health Sector Strategy on Viral Hepatitis 2016-2021 “Towards ending 































































viral hepatitis”, and in order to encourage policy-makers to fulfil the Strategic 
Direction 4 of the WHO Global Health Sector Strategy on Viral Hepatitis 2016-2021, 
and make HCV elimination affordable, we are calling on the European decision 
makers to:
1. Ensure that countries have a comprehensive, costed hepatitis C elimination 
strategy in place, including a comprehensive monitoring along with the cascade of 
care in line with the criteria developed by ECDC and WHO Europe;
2. Determine their country-level disease and economic burden of HCV by measuring 
direct and indirect socio-economic cost to improve the response towards HCV 
elimination, paying attention to the close link between HCV and HIV in some 
populations;
3. Develop country and population-specific models, as viral hepatitis investment 
cases, to estimate lifetime costs, quality-adjusted life expectancy, and incremental 
cost-effectiveness ratios of different screening and treatment strategies with 
comparison with no action;
4. Allocate sufficient resources for training and research, developing robust models 
of care for tackling HCV, and urgently and effectively fulfil Strategic Directions 2, 4 
and 5 of the WHO Global Health Sector Strategy;
5. Recognize the need for the European Union to engage in HCV elimination by 
establishing a clear political road map and call for European financial institutions to 
raise public or private funding and use elimination programss as a development tool;
6. Encourage and engage all the stakeholders to collaborate in the development of 
innovative financing tools like social impact bonds and others, with the aim of 
launching new social services and financing prevention services, including harm 
reduction, contributing to HCV elimination in a sustainable way;
7. Exchange and implement best practices on funding healthcare and HCV 
elimination, including via micro-elimination approaches, at the national, regional and 
local levels to meet the WHO elimination goals by 2030 and preferably much earlier.
































































Address to the 2nd EU HCV Summit “Securing sustainable funding for Hepatitis C 
Virus elimination plans” by George Papandreou, President of Socialist International 
and former prime minister of Greece.
I am honored to address the EU HCV Policy Summits organized by the Hepatitis B and 
C Public Policy Association, for a second time.
I understand that both hepatitis C virus infection and chronic hepatitis C are a public 
health hazard. Yet new safe and effective treatments can cure chronic hepatitis C. 
This represents an historical opportunity, not only to cure those infected but also to 
eliminate this disease globally. 
The World Health Organization has affirmed this possibility by adopting the Global 
Health Sector Strategy to eliminate HCV by 2030. To succeed, we need both good 
diagnostic practices and delivery of treatment for those who are infected.
Still, the total cost of surveillance, awareness campaigns, screening, prevention and 
treatment remains too costly for many around the world. Not surprisingly, the 
economical burden is especially high for the EU countries.
What is however a crucial fact this Summit has highlighted -a fact that policy and 
decision makers need to seriously consider- is that the cost of elimination is lower 
than the cost of treating the long-term consequences of HCV, such us chronic 
hepatitis, cirrhosis and liver cancer.
So, investment towards HCV elimination not only provides cure from suffering but is 
also the best value for money.
We know of course that the up front investment will be high.
The message is that HCV elimination programs are highly cost-effective, cost-saving 
and life saving.
I had the opportunity in the previous Summit, to outline how European Financing 
Institutions could be induced to prepare financing tools and support national HCV 
elimination programs for the European countries. 
I am glad to see that a major part of the analytical work has been finalized and the 
conclusions are presented here during today’s Summit. 
So I would suggest that the next crucial step now, is for the EU Commission to 
prepare the legislative actions, to convincingly motivate the European Investment 
Bank and other European Financial Institutions to take this ambitious yet totally 
realistic project on board.































































I can only conclude by congratulating you all, in this 2nd EU HCV Policy Summit on 
“Securing sustainable funding for Hepatitis C Virus elimination plans”. 
I offer my wishes, and all my support for the best of success
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